On day 35 after tumor challenge, the mice treated with CTGF/E7 DNA vaccine and mTORi (G6: CTGF/E7 DNA vaccine and rapamycin, 1.0 ± 0.2 × 103 mm3; G7: CTGF/E7 DNA vaccine and everolimus, 0.5 ± 0.2 × 103 mm3; G8: CTGF/E7 DNA vaccine and temsirolimus, 1.3 ± 0.3 × 103 mm3) had less tumor volumes than other groups (G1: PBS only, 4.0 ± 0.7 × 103 mm3; G2: CTGF/E7 DNA vaccine, 2.5 ± 0.3 × 103 mm3; G3: rapamycin, 2.4 ± 0.25 × 103 mm3; G4: everolimus, 2.2 ± 0.2 × 103 mm3; G5: temsirolimus, 2.7 ± 0.3 × 103 mm3) (p = 0.002, Figure 7C,D). This evidence concerns the gene CCN2 and neoplasm.